Why the study?
Does irbesartan improve outcomes in patients with heart failure and a preserved left ventricular ejection fraction?
Does irbesartan improve outcomes in patients with heart failure and a preserved left ventricular ejection fraction?
Irbesartan does not improve outcomes in patients with heart failure and preserved ejection fraction.
No support for irbesartan in HFpEF from this cohort; leaves open ARB efficacy pending randomized trials.
Irbesartan did not improve the outcomes of patients with heart failure and a preserved left ventricular ejection fraction. (ClinicalTrials.gov number, NCT00095238.)
No takes yet. Share an insight, caveat, or question.
Massie et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: